Safety Monitoring of <scp>COVID</scp> ‐19 Vaccines: Perspective from the European Medicines Agency-Reference-Cited by-同舟云学术

Safety Monitoring of COVID ‐19 Vaccines: Perspective from the European Medicines Agency

Published:2023-02-06 Issue: Volume: Page:
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Durand Julie¹^ORCID,Dogné Jean‐Michel²,Cohet Catherine³^ORCID,Browne Kate¹,Gordillo‐Marañón María³^ORCID,Piccolo Loris³,Zaccaria Cosimo¹^ORCID,Genov Georgy¹

Affiliation:

1. Pharmacovigilance Office, European Medicines Agency Amsterdam The Netherlands

2. Department of Pharmacy Namur Research Institute for Life Sciences, University of Namur Namur Belgium

3. Data Analytics and Methods Task Force, European Medicines Agency Amsterdam The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2828

Reference61 articles.

1. European Medicines Agency.COVID‐19 guidance: evaluation and marketing authorisation. Accessed August 12 2022.

2. European Medicines Agency.Mvabea European public assessment report. Accessed June 08 2022.

3. European Medicines Agency.Zabdeno European public assessment report. Accessed June 08 2022.

4. European Medicines Agency.Pharmacovigilance Plan of the EU Regulatory Network for COVID‐19 Vaccines. Accessed June 08 2022.

5. Law B.&Sturkenboom M.Safety Platform for Emergency Vaccines: D2.3 Priority List of Adverse events of special interest: COVID‐19. Accessed June 08 2022.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines;Expert Review of Vaccines;2024-09-13

2. The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System;Drug Safety;2024-07-10

3. Myocarditis associated with COVID-19 vaccination;npj Vaccines;2024-06-28

4. The evolving role of disproportionality analysis in pharmacovigilance;Expert Opinion on Drug Safety;2024-06-24

5. COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance;Drug Safety;2024-04-12